Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Virus Vaccine in Healthy Adults

NCT06803342 is registered in ClinicalTrials.gov with Albert B. Sabin Vaccine Institute as lead sponsor.

NCT NCT06803342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06803342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Virus Vaccine in Healthy Adults
Lead sponsor
Albert B. Sabin Vaccine Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 26, 2025
Completion date
April 30, 2027
Enrollment
200 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ebola sudan virus disease